The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Diabetes giant Novo Nordisk looks set to maintain its dominant position in type 2 diabetes, despite recent supply issues affecting its glucagon-like peptide-1 (GLP-1) franchise. 11 November 2022
US Biotech Seagen announced that David Epstein has been appointed as a permanent chief executive and board member, replacing interim CEO Roger Dansey. 11 November 2022
UK pharma major GSK has announced the publication of positive end of study results from the B-Clear Phase IIb trial evaluating bepirovirsen in chronic hepatitis B in the New England Journal of Medicine. 10 November 2022
Shares of USA-based Kronos Bio plunged more than 9% to $2.32 in early trading today, after it announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib, and its CDK9 inhibitor, KB-0742. 10 November 2022
Another healthy set of financial results led to a 3% rise in the share price of Anglo-Swedish pharma major AstraZeneca by late-afternoon Thursday. 10 November 2022
R-Pharm Group, one of Russia’s leading pharmaceutical producers, is expanding into the market Southeast Asia, according to the company, reports The Pharma Letter’s local correspondent. 10 November 2022
News of the planned merger of Norway-based companies Nordic Nanovector and APIM Therapeutics, a privately held, clinical-stage cancer-focused biotechnology firm, saw the former’s shares fall 13.3% to 1.17 Norwegian kroner by late afternoon. 10 November 2022
German drugmaker Merck KGaA has reported net sales in the 2022 third quarter of 5.8 billion euros ($5.8 billion), in line with many analysts’ expectations, with earnings per share coming in at 2.68 euros. 10 November 2022
After months of searching for a new leader, US biotech major Biogen today announced the appointment of industry veteran Christopher Viehbacher as president and chief executive and a member of its board of directors, effective November 14. 10 November 2022
The US Food and Drug Administration (FDA) yesterday issued an emergency use authorization (EUA)for Kineret (anakinra) injection for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) 10 November 2022
The number of drugs that are disappearing from Russian pharmaceutical retail is steadily growing due to ongoing repartition of the market by the largest local players as well as Western sanctions against Russia. 10 November 2022
A strategic licensing deal has been agreed between Barcelona, Spain-based rare disease company Minoryx Therapeutics and German central nervous system (CNS) specialist Neuraxpharm. 10 November 2022
The entry of new treatments for atypical hemolytic uremic syndrome (aHUS) such as Swiss pharmaceutical giants Novartis and Roche that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says data and analytics company GlobalData. 10 November 2022
Shares of Sino-American biotech BeiGene rose as much as 3.8% to 133.97 renminbi when trading started this morning, as the company released third-quarter 2022 financial results that beat consensus forecasts. 10 November 2022
The growing US-China tension, a chilled market and a weakened China economy had Chinese biotechs re-think their strategies. However, most of them agreed that, despite all the challenges, going global is a must, said speakers at the DJSeedin innovation partnering conference held in Shanghai earlier this month. 9 November 2022
Artificial intelligence (AI)-driven drug discovery company Insilico Medicine has announced a multi-year, multi-target strategic research collaboration with French pharma major Sanofi. 9 November 2022
The checkpoint blocker Libtayo (cemiplimab-rwlc) has secured US approval for the first-line treatment of certain adults with advanced non-small cell lung cancer (NSCLC). 9 November 2022
Shares of Novavax were up as much as 3% in pre-market trading, after the US biotech released top-line results from a Phase III boosting trial for COVID-19, showing that its BA.1 vaccine candidate (NVX-CoV2373) met the primary strain-change endpoint. 9 November 2022